Brind.

Investor scrutiny mounts over Oscar Health's financial health following Mark T. Bertolini's appointment as CEO, with questions raised about cash flow and sustainability.

2 reports, 2 independent Updated Aug 13
Gone quiet Reached 2 outlets in its first 24 hours
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Investor scrutiny mounts over Oscar Health's financial health following Mark T. Bertolini's appointment as CEO, with questions raised about cash flow and sustainability.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • StockStoryThe Top 5 Analyst Questions From Oscar Health’s Q2 Earnings Call Oscar Health’s second quarter was marked by robust top-line growth, but the company missed Wall Street’s revenue and non-GAAP EPS esti
  • Business WireOscar Health Announces Financial Results for Second Quarter 2025 and Reaffirms Updated 2025 Guidance NEW YORK, August 06, 2025--(BUSINESS WIRE)--Oscar Health, Inc. ("Oscar" or the "Company") (NYSE: O